Nanobiotix (EPA: NANO) net income
Nanobiotix reported a net loss of €24.0m for fiscal 2025; in fiscal 2024 it reported a net loss of €68.1m. Earnings per share were −€0.50.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −€24.0m | — | −80.8% | −€0.50 |
| 2024 | −€68.1m | — | — | −€1.44 |
| 2023 | −€39.7m | — | −132.1% | −€1.08 |
| 2022 | −€57.0m | — | −1,194.3% | −€1.64 |
| 2021 | −€47.0m | — | −1,775.7% | −€1.35 |
| 2020 | −€33.6m | — | −1,337.2% | −€1.38 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the net income of Nanobiotix
- How much did Nanobiotix earn in fiscal 2025?
- Nanobiotix reported a net loss of €24.0m for fiscal 2025. In fiscal 2024 it reported a net loss of €68.1m.
- What are the earnings per share of Nanobiotix?
- They were −€0.50 in fiscal 2025, compared with −€1.44 in fiscal 2024.
- Where do the figures for Nanobiotix come from?
- From the report Nanobiotix files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Nanobiotix files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Nanobiotix: the Nanobiotix page · annual accounts · revenue.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.